Founded in 2021, TerThera strives to meet the growing global demand for radionuclides in cancer healthcare by providing a highly sustainable and uninterrupted supply of Terbium-161 for use in radioligand therapy. 

Terbium-161 HCl produced at the highest radiochemical grade under non-GMP conditions, available in 0.05M HCl Solution. 

Current intended use: not for direct administration to humans.

Using PSMA and SST analogues, Terbium-161 has shown excellent bioequivalence presenting a biodistribution comparable to the currently used radiolanthanides. Additionally, the 16-fold increase in Auger and conversion electrons is expected to improve the cellular absorbed dose

Terbium-161, compared to current standard radiolanthanides, provides for an immediate decrease in dose rate allowing a significant improvement in general radiation safety. This optimization of radiation safety may extend current treatment room capacity for Radioligand Therapy.